France Legalizes CBD Cannabis Derived Products with THC below 0.3%

Jan.06.2023
France Legalizes CBD Cannabis Derived Products with THC below 0.3%
France legalizes sales of CBD-derived products with THC up to 0.3% but still bans sales of unprocessed cannabis flowers.

According to French media outlet RFI, on December 30th, 2021, the French government legalized the sale of cannabis-derived products containing CBD, with a THC content of no more than 0.3%, one year after lifting the ban on CBD. However, cannabis enthusiasts and those who favor Delta-8 (D8) may be disappointed to learn that the government still prohibits the sale of cannabis flowers, citing their supposed psychoactive effects.


However, a high court in France overturned the ban, ruling that CBD has not been proven harmful and that there are other legal uses for the plant besides smoking.


On December 29th, the French State Council (an institution that provides legislative proposals to the government and serves as the highest court) ruled that a comprehensive and absolute ban on the sale of raw forms of CBD was "disproportionate." They also found no conclusive evidence of harm from CBD. If any evidence exists, it is to the contrary.


The harmful effects of other molecules present in cannabis flowers and leaves, particularly CBD, have not yet been determined," the committee said. The committee added that there is evidence to suggest that CBD has "relaxing properties and anti-seizure effects, but no psychoactive effects, nor does it cause dependency.


In other words, the court ruled that marijuana should not automatically be classified as a psychoactive drug, as this is far from the truth. Additionally, it can be used not only for smoking, but also for making tea or infused oil. Other factors to consider are homemade tinctures or vaporizing the flowers.


Concerns about distinguishing between different types of cannabis.


Despite the recent court ruling allowing for cannabis cultivation, concerns have been raised about the government's plans to distinguish between cannabis and its highly potent derivative, tetrahydrocannabinol (THC), which is nearly indistinguishable to the naked eye. The State Council maintains that THC levels "can be controlled through rapid testing.


In November 2020, the European Court ruled that a ban on CBD that is legal in other European countries is illegal in France, based on the principle of free movement of goods.


The highest court of justice in France ruled in June of last year that any CBD produced legally in the European Union can be sold legally in France.


According to the French Professional Cannabis Association (SPC), as reported by RFI, there are now approximately 2,000 CBD shops operating in France. The industry's annual turnover is estimated to be around €500 million, or $534.1 million USD. More than half of these sales come solely from flowers.


Experts in the country have stated that the latest court ruling provides a green light for the economically sustainable cannabis industry that can withstand the test of time.


According to a report by Hemp Today, the French Senate committee has stated that legalizing cannabis in France could generate an annual revenue of 1.5 euros (160 billion USD) to 2.5 billion euros (260 billion USD) and create between 18,000-20,000 job opportunities.


The French extractive trade group, UIVEC, estimates that the grey market for CBD in France will be worth around 200 million euros ($214 million) by 2021, and is expected to reach about 300 million euros ($321 million) this year. UIVEC also estimates that by 2022, approximately 300-500 hectares of cannabis will be grown for hemp flower CBD production.


As legislation moves forward, these regulations are expected to be implemented in early 2023. The government is expected to announce that marijuana is in compliance with the European Union's common agriculture policy, develop an industry strategy, and create specific regulations.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

NAS 2026 | Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
NAS 2026 | Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
Cliff Douglas, a veteran U.S. tobacco-control and public health policy figure, told NAS 2026 that the “continuum of risk” should play a central role in tobacco policy. He called for clearer market pathways, stronger risk communication, differentiated regulation and enforcement, and said possible FDA reforms to PMTA reviews could be a “welcome correction” if they create a more efficient, predictable route for scientifically substantiated lower-risk products. Read 2Firsts’ on-site coverage.
Sep.26
Product | Philip Morris Launches TEREA Bold Red and Bold Black in Germany With Level-10 Tobacco Intensity at €8 per Pack
Product | Philip Morris Launches TEREA Bold Red and Bold Black in Germany With Level-10 Tobacco Intensity at €8 per Pack
Philip Morris International (PMI) introduced TEREA Bold Red and Bold Black heated tobacco sticks in Germany in October 2026, both carrying a brand-rated tobacco-flavor intensity of 10, the highest level in the country's TEREA portfolio. Bold Red features leather and warm woody notes, while Bold Black combines woody and subtle floral notes. Both are sold in 20-stick packs at €8, approximately 2.6% above standard TEREA products. Germany's TEREA range now includes 11 flavor variants, alongside a separate 26-stick XL format priced at €10. IQOS Germany announced the new products on October 12, followed by a phased retail rollout from late October and an IQOS Club campaign running through December.
product
Nov.02
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
Special Report|From CrossBar 20K to 6-Methyl Nicotine KUMI: Two Routes Into U.S. State Vape Directories?
Special Report|From CrossBar 20K to 6-Methyl Nicotine KUMI: Two Routes Into U.S. State Vape Directories?
Several U.S. states have incorporated the September 9, 2020 PMTA filing deadline into eligibility rules for certain vaping products. CrossBar 20K drew attention after appearing on Pennsylvania's 163-entry directory. A broader 2Firsts investigation found that related registration businesses also listed KUMI and CROSSBAR SIX products, with 171 KUMI-related entries across Louisiana, Nebraska and Wisconsin. Corporate records link Scott Silverman to Blue Nine LLC and VR Products I LLC. PMTA compliance expert Mr. K said historical applications and nicotine-analogue products may offer two different approaches to state-directory access.
Regulations
Oct.26
Product | DOJO Launches 0+6ml BLAST7K Fresh in UK in September, Retaining 2+8ml Pod Compatibility Ahead of October Per-Milliliter Vaping Duty
Product | DOJO Launches 0+6ml BLAST7K Fresh in UK in September, Retaining 2+8ml Pod Compatibility Ahead of October Per-Milliliter Vaping Duty
DOJO officially launched the BLAST7K Fresh on September 17, 2026, introducing a UK-market prefilled pod product with 6ml of e-liquid and a manufacturer-rated capacity of up to 7,000 puffs. The device features a 1000mAh rechargeable battery, the INSTA-JUICED structure and COREX BLAST dual-mesh technology, while retaining compatibility with existing BLAST pods. The launch comes less than two weeks before the UK's Vaping Products Duty takes effect on October 1. At the new duty rate, 6ml of vaping liquid would correspond to £1.32 in VPD. DOJO has not stated that the product's 6ml format was designed in response to the new duty.
Sep.20
PMI Plans $71 Million Philippine Smoke-Free Expansion: BLENDS Production Established, Batangas Plant Exports to 18 Markets
PMI Plans $71 Million Philippine Smoke-Free Expansion: BLENDS Production Established, Batangas Plant Exports to 18 Markets
Philip Morris International (PMI) plans to invest approximately PHP 4.5 billion ($71 million) to expand its existing smoke-free manufacturing facility in Tanauan, Batangas, in the Philippines. The expansion is expected to be completed in 2027, with additional capacity serving domestic and export markets. The facility began manufacturing heated tobacco consumables in April 2024, including BLENDS sticks for the BONDS by IQOS platform. Philippine business media reported in October 2026 that products from the Batangas plant were being exported to 18 markets across Asia and Europe. PMI says it has invested more than $2 billion in the Philippines since 2010. The expansion adds to the country's existing manufacturing and export role within PMI's international supply chain.
company
Nov.16